This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. More information about cookies is available in our privacy policy

Recent Myeloma ResearchExplore Recent Findings in Myeloma Research

See why aiming for MRD negativity may be an optimal strategy for patients with high-risk cytogenetics.

MRD negativity strategy for patients with high-risk cytogenetics, Downloadable resource.SEE THE FINDINGS

Review evidence of the importance of frailty assessment when treating the ageing patient with myeloma.

The importance of frailty assessment when treating ageing patient with Multiple Myeloma, Downloadable resource.SEE THE FINDINGS

Learn about how high attrition rates underscore the importance of maximising PFS in early lines of therapy.

High attrition rates and the importance of using your best therapy first, Downloadable resource.SEE THE FINDINGS

MRD=minimal residual disease.

211125_SANOFI_LOGO_RGB Copy
Myeloma FactsContactSite MapLegal NoticePrivacy & Data ProtectionCookies Policy

©2024 Sanofi-aventis Groupe. All rights reserved. Sanofi is a registered trademark of Sanofi or an affiliate.

MAT-GLB-2200930(V2.0) 10/23 MAT.US.2203027-v2.0-10/2023